MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)
Clinical trials for MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD) explained in plain language.
Never miss a new study
Get alerted when new MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD) trials appear
Sign up with your email to follow new studies for MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising drug aims to stop MOGAD attacks in their tracks
Disease control Recruiting nowThis study tests a drug called satralizumab to see if it can prevent relapses in people with MOGAD, a rare autoimmune disease that attacks the brain and spinal cord. About 152 participants aged 12 and older will receive either the drug or a placebo. The main goal is to measure ho…
Matched conditions: MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 26, 2026 02:07 UTC
-
Super MRI scans aim to unlock secrets of brain resilience
Knowledge-focused Recruiting nowThis study uses powerful MRI scanners to look at the brains of 700 people, including those with conditions like multiple sclerosis, Alzheimer's, and Parkinson's, as well as healthy volunteers. The goal is to understand why some brains stay healthy while others develop disease. Re…
Matched conditions: MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)
Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated May 13, 2026 16:00 UTC